{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:19:17Z","timestamp":1794745157014,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119983","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:24:27Z","timestamp":1791933867000},"page":"119983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of hydrogen sulfide inhibition as an adjunct to gemcitabine and BCG therapy in non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3941-5605","authenticated-orcid":false,"given":"Liam","family":"McFarlane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-7202","authenticated-orcid":false,"given":"George J.","family":"Dugbartey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Shamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alp","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119983_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119983_bib2","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119983_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756287211431976","article-title":"Best practice in the treatment of nonmuscle invasive bladder cancer","volume":"4","author":"Anastasiadis","year":"2012","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.biopha.2026.119983_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119983_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biopha.2026.119983_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.biopha.2026.119983_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clin. Outcomes Res."},{"key":"10.1016\/j.biopha.2026.119983_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus calmette-gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.biopha.2026.119983_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119983_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001015816.87470.c9.01","article-title":"P2-01 TAR-200 in patients with bacillus calmette\u2013Gu\u00e9rin-unresponsive high-risk non\u2013muscle-invasive bladder cancer: results from sunrise-1 study","author":"Necchi","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119983_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.abb.2016.06.010","article-title":"Cystathionine: a novel oncometabolite in human breast cancer","volume":"604","author":"Sen","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2026.119983_bib12","first-page":"473","article-title":"Cystathionine\u2011\u03b3\u2011lyase promotes the metastasis of breast cancer via the VEGF signaling pathway","volume":"55","author":"Wang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119983_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/pathophysiology28030028","article-title":"Molecular functions of hydrogen sulfide in cancer","volume":"28","author":"Shackelford","year":"2021","journal-title":"Pathophysiology"},{"key":"10.1016\/j.biopha.2026.119983_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241263726","article-title":"Cystathionine-\u03b2-synthase expression correlates with tumour progression and adverse prognosis in patients with colon cancer","volume":"52","author":"Hu","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.biopha.2026.119983_bib15","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1073\/pnas.1306241110","article-title":"Tumor-derived hydrogen sulfide, produced by cystathionine-\u03b2-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer","volume":"110","author":"Szabo","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119983_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079167","article-title":"Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance","volume":"8","author":"Bhattacharyya","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119983_bib17","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.21873\/invivo.12102","article-title":"Patterns of expression of H2S-producing enzyme in human renal cell carcinoma specimens: potential avenue for future therapeutics","volume":"34","author":"Sogutdelen","year":"2020","journal-title":"Vivo"},{"key":"10.1016\/j.biopha.2026.119983_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201845986","article-title":"Dysregulation of cystathionine \u03b3-lyase promotes prostate cancer progression and metastasis","volume":"20","author":"Wang","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2026.119983_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.06.020","article-title":"Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder","volume":"34","author":"Gai","year":"2016","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.biopha.2026.119983_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4103\/jcrt.JCRT_423_17","article-title":"Effects of exogenous hydrogen sulfide on the proliferation and invasion of human Bladder cancer cells","volume":"13","author":"Liu","year":"2017","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.biopha.2026.119983_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/ph17091212","article-title":"Pharmacological inhibition of endogenous hydrogen sulfide production slows bladder cancer progression in an intravesical murine model","volume":"17","author":"Relouw","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2026.119983_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/ars.2017.7009","article-title":"Biogenesis of hydrogen sulfide and thioethers by cystathionine beta-synthase","volume":"28","author":"Majtan","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2026.119983_bib23","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1074\/jbc.M808026200","article-title":"H2S biogenesis by human cystathionine \u03b3-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia","volume":"284","author":"Chiku","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119983_bib24","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ncomms2371","article-title":"A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells","volume":"4","author":"Shibuya","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119983_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bcp.2017.10.007","article-title":"Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells","volume":"149","author":"Untereiner","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119983_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2019.09.006","article-title":"Inhibition of hydrogen sulfide synthesis reverses acquired resistance to 5-FU through miR-215-5p-EREG\/TYMS axis in colon cancer cells","volume":"466","author":"Chen","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119983_bib27","first-page":"57691","article-title":"Optimized scratch assay for in vitro testing of cell migration with an automated optical camera","author":"Vang Mouritzen","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2026.119983_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217339","article-title":"Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications","volume":"610","author":"Jeong","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119983_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/BLC-180167","article-title":"Systematic review: characteristics and preclinical uses of bladder cancer cell lines","volume":"4","author":"Zuiverloon","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.biopha.2026.119983_bib30","first-page":"8484","article-title":"Increased H2S and its synthases in urothelial cell carcinoma of the bladder, and enhanced cisplatin\u2011induced apoptosis following H2S inhibition in EJ cells","volume":"15","author":"Wahafu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2026.119983_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1089\/ars.2014.5933","article-title":"The therapeutic potential of cystathionine \u03b2-synthetase\/hydrogen sulfide inhibition in cancer","volume":"22","author":"Hellmich","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2026.119983_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113775","article-title":"Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1\u03b1 activation","volume":"172","author":"Wang","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119983_bib33","article-title":"PI3K p110\u03b1 isoform-dependent Rho GTPase Rac1 activation mediates H2S-promoted endothelial cell migration via actin cytoskeleton reorganization","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119983_bib34","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3892\/or.2016.5014","article-title":"Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, migration effects and accelerates cell cycle progression in multiple myeloma cells via activating the Akt pathway","volume":"36","author":"Zheng","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119983_bib35","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.3390\/molecules27134049","article-title":"Pharmacological inhibition of endogenous hydrogen sulfide attenuates breast cancer progression","volume":"27","author":"Khan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119983_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119983_bib37","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.chembiol.2021.05.016","article-title":"Intracellular H2S production is an autophagy-dependent adaptive response to DNA damage","volume":"28","author":"Jiang","year":"2021","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119983_bib38","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1074\/jbc.M115.685578","article-title":"Transcriptional regulation of cystathionine-\u03b3-lyase in endothelial cells by NADPH oxidase 4-dependent signaling","volume":"291","author":"Mistry","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119983_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.mcb.2020.10.020","article-title":"BBN-driven urinary bladder cancer mouse model","volume":"163","author":"Korac-Prlic","year":"2021","journal-title":"Methods Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119983_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99746-3","article-title":"Metabolomic credentialing of murine carcinogen-induced urothelial cancer","volume":"11","author":"Afify","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119983_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.18632\/oncoscience.439","article-title":"The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3\/MLL4 genetic disruption","volume":"5","author":"Fantini","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.biopha.2026.119983_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119983_bib43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12967-019-02146-5","article-title":"The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice","volume":"17","author":"Degoricija","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119983_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95157-6","article-title":"MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model","volume":"11","author":"de Queiroz","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119983_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3892\/etm.2014.2060","article-title":"Efficacy of intravesical Bacillus Calmette-Gu\u00e9rin therapy against tumor immune escape in an orthotopic model of bladder cancer","volume":"9","author":"HUANG","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biopha.2026.119983_bib46","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","article-title":"A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer","volume":"37","author":"Fantini","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119983_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.immuni.2015.07.017","article-title":"Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory t cell differentiation and maintain immune homeostasis","volume":"43","author":"Yang","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2026.119983_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jare.2020.07.006","article-title":"Targeting hydrogen sulphide signaling in breast cancer","volume":"27","author":"Youness","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biopha.2026.119983_bib49","article-title":"A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer","author":"Escano","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119983_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4137\/CMO.S7658","article-title":"Antitumor efficacy of intravesical BCG, gemcitabine, interferon-\u03b1 and interleukin-2 as mono- or combination-therapy for bladder cancer in an orthotopic tumor model","volume":"5","author":"Xiao","year":"2011","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.biopha.2026.119983_bib51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jnci\/djk113","article-title":"Promotion of bladder cancer development and progression by androgen receptor signals","volume":"99","author":"Miyamoto","year":"2007","journal-title":"JNCI Journal National Cancer Institute"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222601019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222601019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:51:14Z","timestamp":1794743474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222601019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S075333222601019X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119983","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of hydrogen sulfide inhibition as an adjunct to gemcitabine and BCG therapy in non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119983"}}